Brainsway Ltd Sponsored ADR Aktie News

BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tu...

R ecent agreements with two additional U.S. mental health providers bring total to four in 2025

This investment marks BrainsWay's entrance into the market for mental health therapies that can be administered outside of a clinic, including at home

The Investment is part of BrainsWay's ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care The Investment is part of BrainsWay's ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care

BrainsWay Ltd. (NASDAQ:BWAY ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call Participants Carl Edward Byrnes - Northland Capital Markets, Research Division Jeffrey Scott Cohen - Ladenburg Thalmann & Co. Inc., Research Division Garth Russell - Unidentified Company Operator G...

Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2025 Revenue and EBITDA guidance Remaining performance obligations increased by 25% YOY to $62 million Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 13, 2025 (...

Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trial Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trial

BURLINGTON, Mass. and JERUSALEM, June 10, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd.